Japanese orthopaedic association (JOA) clinical practice guideline on the management of primary malignant bone tumors - Secondary publication
Year: 2024
Type: article
Abstract: BACKGROUND: In Japan, there are currently no general guidelines for the treatment of primary malignant bone tumors. Therefore, the Japanese Orthopaedic Association established a committee to develop guidelines for the appropriate diagnosis and treatment of primary malignant bone tumors for medical professionals in clinical practice. METHODS: The guidelines were developed in accordance with "Minds Clinical Practice Guideline Development Handbook 2014″ and "Minds Clinical Practice Guideline Development Manual 2017". The Japanese Orthopaedic Association's Bone and Soft Tissue Tumor Committee established guideline development and systematic review committees, drawing members from orthopedic specialists leading the diagnosis and treatment of bone and soft tissue tumors. Pediatricians, radiologists, and diagnostic pathologists were added to both committees because of the importance of multidisciplinary treatment. Based on the diagnosis and treatment algorithm for primary malignant bone tumors, important decision-making points were selected, and clinical questions (CQ) were determined. The strength of recommendation was rated on two levels and the strength of evidence was rated on four levels. The recommendations published were selected based on agreement by 70% or more of the voters. RESULTS: The guideline development committee examined the important clinical issues in the clinical algorithm and selected 22 CQs. The systematic review committee reviewed the evidence concerning each CQ and a clinical value judgment was added by experts. Eventually, 25 questions were published and the text of each recommendation was determined. CONCLUSION: Since primary malignant bone tumors are rare, there is a dearth of strong evidence based on randomized controlled trials, and recommendations cannot be applied to all the patients. In clinical practice, appropriate treatment of patients with primary malignant bone tumors should be based on the histopathological diagnosis and degree of progression of each case, using these guidelines as a reference.
Source: Journal of Orthopaedic Science
Institutions: Toho University, Kobe University, Japan Community Healthcare Organization, Sendai Shakai Hoken Hospital, Teikyo University, Sapporo National Hospital, National Cancer Centre Japan, National Cancer Center Hospital East, Hyogo Medical University, Kyorin University, Tokyo Medical Center, National Hospital Organization, Nagoya University Hospital, Kyushu University, Niigata University Medical and Dental Hospital, Kure Medical Center, Dokkyo Medical University Nikko Medical Center, Kagawa University Hospital, Japan Council for Quality Health Care, International University of Health and Welfare
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,000
Awards: Development of novel osteoclast differentiation inhibitors aimed at reducing complications, Basic research of genomic medicine for bone metastasis of unknown primary aming at precision medicine, Analysis of the immune environment and development of novel therapies in intermediate group bone and soft tissue tumors
OpenAlex ID: W4400575841